Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewAIDS/HIVImmunologyInfectious disease Open Access | 10.1172/jci.insight.193752

Co-administration of Rapamycin with a DNA/MVA SIV Vaccine Improves Memory CD8 T Cell Response

Shanmugalakshmi Sadagopal,1 Kasey Stokdyk,2 Suefen Kwa,2 Rahul Basu,2 Sailaja Gangadhara,1 Rafi Ahmed,3 Smita S. Iyer,1 Koichi Araki,3 and Rama Rao Amara1

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Sadagopal, S. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Stokdyk, K. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Kwa, S. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Basu, R. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Gangadhara, S. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Ahmed, R. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Iyer, S. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Araki, K. in: PubMed | Google Scholar

1Emory Vaccine Center, Emory University, Atlanta, United States of America

2Emory Vaccine Center, Emory Univeristy, Atlanta, United States of America

3Department of Microbiology and Immunology, Emory University, Atlanta, United States of America

Find articles by Amara, R. in: PubMed | Google Scholar |

Published April 23, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.193752.
Copyright © 2026, Sadagopal et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published April 23, 2026 - Version history
View PDF
Abstract

Inhibiting the mammalian target of rapamycin (mTOR) during acute viral infection generates highly functional memory CD8 T cells. We investigated the effects of inhibiting mTOR by using rapamycin during the effector and contraction phases of the immune response to a DNA prime and Modified Vaccinia Ankara (MVA) boost SIV vaccination in rhesus macaques. Rapamycin administered either during MVA boosts alone (DMR) or during both primes and boosts (DRMR) reduced the contraction of effector CD8 T cells, resulting in higher frequencies of SIV-specific memory CD8 T cells with enhanced quality as indicated by expression of Bcl-2 and CD127. Additionally, rapamycin reduced the frequency of proliferating CCR5+ CD4 T cells in the blood following the MVA boost. Post SIV251 infection, rapamycin-treated macaques demonstrated marked expansion of SIV-specific CD8 T cells (reaching up to 50% in blood and 25% in gut). The heightened expansion of SIV-specific CD8 T cells in the DMR group was associated with markedly lower (2-logs compared to unvaccinated and 1-log compared to DM) peak viral load in the gut and set-point viremia, along with improved survival post infection. Thus, inhibiting the mTOR pathway during MVA boosts of a DNA/MVA vaccine enhances vaccine efficacy by improving memory CD4 and CD8 T cell function.

Supplemental material

View

Version history
  • Version 1 (April 23, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts